Antitumor effect of periplocin in TRAIL-resistant human hepatocellular carcinoma cells through downregulation of IAPs

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Cheng, Chieh Fang ^a   Lu, I Huang ^a   Tseng, Hsiang Wen ^a   Sun, Chung Yuan ^a   Lin, Li Tsen ^a   Kuo, Zong Keng ^a   Pan, I Horng ^a   Ko, Ching Huai ^a  

^a INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HERBACEOUS AGENT; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PERIPLOCIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN MCL 1; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84872782713     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/958025     Document Type: Article

References (42)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010 60 277 300
2. Llovet J. M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J. F., De Oliveira A. C., Santoro A., Raoul J. L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T. F., Galle P. R., Seitz J. F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J., Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008 359 4 378 390 2-s2.0-47949116252 10.1056/NEJMoa0708857
3. Numata M., Yamamoto A., Moribayashi A., Yamada H., Antitumor components isolated from the Chinese herbal medicine Coix lachryma-jobi. Planta Medica 1994 60 4 356 359 2-s2.0-0027934132 10.1055/s-2006-959500 (Pubitemid 24255932)
4. Su M., Chung H. Y., Li Y., 6- O -Angeloylenolin induced cell-cycle arrest and apoptosis in human nasopharyngeal cancer cells. Chemico-Biological Interactions 2011 189 167 176 10.1016/j.cbi.2010.12.022
5. Ohba H., Moriwaki S., Bakalova R., Yasuda S., Yamasaki N., Plant-derived abrin-a induces apoptosis in cultured leukemic cell lines by different mechanisms. Toxicology and Applied Pharmacology 2004 195 182 193 10.1016/j.taap.2003.11.018 (Pubitemid 38293150)
6. Priyadarsini R. V., Murugan R. S., Sripriya P., Karunagaran D., Nagini S., The neem limonoids azadirachtin and nimbolide induce cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells. Free Radical Research 2010 44 6 624 634 2-s2.0-77953607616 10.3109/10715761003692503
7. Zhao L., Shan B., Du Y., Wang M., Liu L., Ren F. Z., Periplocin from Cortex periplocae inhibits cell growth and down-regulates survivin and c-myc expression in colon cancer in vitro and in vivo via β -catenin/TCF signaling. Oncology Reports 2010 24 2 375 383 2-s2.0-77954381626 10.3892/or-00000870
8. Lu Z. J., Zhou Y., Song Q., Qin Z., Zhang H., Zhou Y. J., Gou L. T., Yang J. L., Luo F., Periplocin inhibits growth of lung cancer in vitro and in vivo by blocking AKT/ERK signaling pathways. Cellular Physiology and Biochemistry 2010 26 609 618 10.1159/000322328
9. Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C. P., Nicholl J. K., Sutherland G. R., Smith T. D., Rauch C., Smith C. A., Goodwin R. G., Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995 3 6 673 682 2-s2.0-13344285339 10.1016/1074-7613(95)90057-8 (Pubitemid 26091143)
10. Pan G., O'Rourke K., Chinnaiyan A. M., Gentz R., Ebner R., Ni J., Dixit V. M., The receptor for the cytotoxic ligand TRAIL. Science 1997 276 5309 111 113 2-s2.0-0030996297 10.1126/science.276.5309.111 (Pubitemid 27161256)
11. Chaudhary P. M., Eby M., Jasmin A., Bookwalter A., Urray J. M., Hood L., Death receptor 5, a new member of the TNFR family, and DR4 induce FADD- dependent apoptosis and activate the NF- B pathway. Immunity 1997 7 6 821 830 2-s2.0-0031406386 10.1016/S1074-7613(00)80400-8 (Pubitemid 28064895)
12. Smyth M. J., Takeda K., Hayakawa Y., Peschon J. J., van den Brink M. R., Yagita H., Nature's TRAIL-on a path to cancer immunotherapy. Immunity 2003 18 1 6 10.1016/S1074-7613(02)00502-2 (Pubitemid 36120682)
13. Cretney E., Shanker A., Yagita H., Smyth M. J., Sayers T. J., TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunology & Cell Biology 2006 84 87 98 10.1111/j.1440-1711.2005.01413.x
14. Van Geelen C. M. M., De Vries E. G. E., De Jong S., Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resistance Updates 2004 7 6 345 358 2-s2.0-14844288360 10.1016/j.drup.2004.11.002 (Pubitemid 40341956)
15. Zhang Y., Zhang B., TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Molecular Cancer Research 2008 6 1861 1871 10.1158/1541-7786.MCR-08-0313
16. Chen K., Tu Y., Zhang Y., Blair H. C., Zhang L., Wu C., PINCH-1 regulates the ERK-Bim pathway and contributes to apoptosis resistance in cancer cells. The Journal of Biological Chemistry 2008 283 2508 2517
17. Khanbolooki S., Nawrocki S. T., Arumugam T., Andtbacka R., Pino M. S., Kurzrock R., Logsdon C. D., Abbruzzese J. L., McConkey D. J., Nuclear factor- B maintains TRAIL resistance in human pancreatic cancer cells. Molecular Cancer Therapeutics 2006 5 9 2251 2260 2-s2.0-33749578608 10.1158/1535-7163.MCT-06-0075 (Pubitemid 44530462)
18. Zhang L., Zhu H., Davis J. J., Jacob D., Wu S., Teraishi F., Gutierrez A., Wang Y., Fang B., Lack of p38 MAP kinase activation in TRAIL-resistant cells is not related to the resistance to TRAIL-mediated cell death. Cancer Biology and Therapy 2004 3 3 296 301 2-s2.0-14644420166 (Pubitemid 41350883)
19. Rosato R. R., Almenara J. A., Coe S., Grant S., The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Research 2007 67 19 9490 9500 2-s2.0-35148900795 10.1158/0008-5472.CAN-07-0598 (Pubitemid 47535939)
20. Yang J. F., Cao J. G., Tian L., Liu F., 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells. Cancer Chemotherapy and Pharmacology 2012 69 195 206 10.1007/s00280-011- 1686-9
21. Ko C. H., Shen S. C., Chen Y. C., Hydroxylation at C4′ or C6 is essential for apoptosis-inducing activity of flavanone through activation of the caspase-3 cascade and production of reactive oxygen species. Free Radical Biology and Medicine 2004 36 7 897 910 2-s2.0-1542395634 10.1016/j. freeradbiomed.2003.12.020 (Pubitemid 38352906)
22. Pellerito O., Calvaruso G., Portanova P., De Blasio A., Santulli A., Vento R., Tesoriere G., Giuliano M., The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. Molecular Pharmacology 2010 77 5 854 863 2-s2.0-77951043153 10.1124/mol.109.062257
23. Ding W., Cai T., Zhu H., Wu R., Tu C., Yang L., Lu W., He Q., Yang B., Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo. Cancer Letters 2010 293 158 166 10.1016/j.canlet.2010.01.005
24. Hayakawa Y., Screpanti V., Yagita H., Grandien A., Ljunggren H. G., Smyth M. J., Chambers B. J., NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. Journal of Immunology 2004 172 1 123 129 2-s2.0-0347364696 (Pubitemid 38020463)
25. Smyth M. J., Cretney E., Takeda K., Wiltrout R. H., Sedger L. M., Kayagaki N., Yagita H., Okumura K., Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ -dependent natural killer cell protection from tumor metastasis. Journal of Experimental Medicine 2001 193 6 661 670 2-s2.0-0035911242 10.1084/jem.193.6.661 (Pubitemid 32524460)
26. Zhang H., Qian D. Z., Tan Y. S., Lee K., Gao P., Ren Y. R., Rey S., Hammers H., Chang D., Pili R., Dang C. V., Liu J. O., Semenza G. L., Digoxin and other cardiac glycosides inhibit HIF-1 synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America 2008 105 50 19579 19586 2-s2.0-58149374576 10.1073/pnas.0809763105
27. Stenkvist B., Is digitalis a therapy for breast carcinoma? Oncology Reports 1999 6 493 496
28. Stenkvist B., Pengtsson E., Dahlqvist B., Eriksson O., Jarkrans T., Nordin B., Cardiac glycosides and breast cancer, revisited. The New England Journal of Medicine 1982 306 8, article 484
29. Qi F., Inagaki Y., Gao B., Cui X., Xu H., Kokudo N., Li A., Tang W., Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Science 2011 102 5 951 958 2-s2.0-79954672344 10.1111/j.1349-7006.2011.01900.x
30. Lin H., Juang J. L., Wang P. S., Involvement of Cdk5/p25 in digoxin-triggered prostate-cancer cell apoptosis. Journal of Biological Chemistry 2004 279 28 29302 29307 2-s2.0-3142689920 10.1074/jbc.M403664200 (Pubitemid 38915807)
31. Ramirez-Ortega M., Zarco G., Maldonado V., Carrillo J. F., Ramos P., Ceballos G., Melendez-Zajgla J., Garcia N., Zazueta C., Chanona J., Suarez J., Pastelin G., Is digitalis compound-induced cardiotoxicity, mediated through guinea-pig cardiomyocytes apoptosis? European Journal of Pharmacology 2007 566 1-3 34 42 2-s2.0-34249286278 10.1016/j.ejphar.2007.03.033 (Pubitemid 46805093)
32. Suliman A., Lam A., Datta R., Srivastava R. K., Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001 20 17 2122 2133 2-s2.0-0035912060 10.1038/sj.onc.1204282 (Pubitemid 32424006)
33. Degli-Esposti M. A., Smolak P. J., Walczak H., Waugh J., Huang C. P., DuBose R. F., Goodwin R. G., Smith C. A., Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. Journal of Experimental Medicine 1997 186 7 1165 1170 2-s2.0-0030869432 10.1084/jem.186.7.1165 (Pubitemid 27441160)
34. Degli-Esposti M. A., Dougall W. C., Smolak P. J., Waugh J. Y., Smith C. A., Goodwin R. G., The novel receptor TRAIL-R4 induces NF- B and protects against TRAIL- mediated apoptosis, yet retains an incomplete death domain. Immunity 1997 7 6 813 820 2-s2.0-0031414749 10.1016/S1074-7613(00)80399-4 (Pubitemid 28064894)
35. Emery J. G., McDonnell P., Burke M. B., Deen K. C., Lyn S., Silverman C., Dul E., Appelbaum E. R., Eichman C., DiPrinzio R., Dodds R. A., James I. E., Rosenberg M., Lee J. C., Young P. R., Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biological Chemistry 1998 273 23 14363 14367 2-s2.0-7344233085 10.1074/jbc.273.23.14363 (Pubitemid 28319153)
36. Eggert A., Grotzer M. A., Zuzak T. J., Wiewrodt B. R., Ho R., Ikegaki N., Brodeur G. M., Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced Apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Research 2001 61 4 1314 1319 2-s2.0-0035866396 (Pubitemid 34292549)
37. Daniel P. T., Wieder T., Sturm I., Schulze-Osthoff K., The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001 15 7 1022 1032 2-s2.0-0034900902 10.1038/sj.leu.2402169 (Pubitemid 32717270)
38. Deveraux Q. L., Reed J. C., IAP family proteins-suppressors of apoptosis. Genes & Development 1999 13 239 252 10.1101/gad.13.3.239 (Pubitemid 29095796)
39. Tamm I., Wang Y., Sausville E., Scudiero D. A., Vigna N., Oltersdorf T., Reed J. C., IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas (CD95), bax, caspases, and anticancer drugs. Cancer Research 1998 58 23 5315 5320 2-s2.0-0032403126 (Pubitemid 28551107)
40. Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C. P., Nicholl J. K., Sutherland G. R., Smith T. D., Rauch C., Smith C. A., Goodwin R. G., Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995 3 6 673 682 2-s2.0-13344285339 10.1016/1074-7613(95)90057-8 (Pubitemid 26091143)
41. + T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004 104 8 2418 2424 2-s2.0-4944243249 10.1182/blood-2004-04-1294 (Pubitemid 39331842)
42. Longman D., Callow J. A., Specific saccharide residues are involved in the recognition of plant root surfaces by zoospores of Pythium aphanidermatum. Physiological and Molecular Plant Pathology 1987 30 1 139 150 2-s2.0-38249036748